These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6230369)

  • 41. In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis.
    Heessen FW; Muytjens HL
    Antimicrob Agents Chemother; 1984 Jan; 25(1):123-4. PubMed ID: 6230988
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro susceptibility of methicillin-resistant Staphylococcus aureus to imipenem and other antimicrobial agents.
    Ishag AJ; Durgham SM; Shibl AM
    Chemioterapia; 1987 Aug; 6(4):261-3. PubMed ID: 3477333
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro and in vivo antibacterial activity of AT-2266.
    Kouno K; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1983 Jul; 24(1):78-84. PubMed ID: 6226242
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates.
    Khan MY; Gruninger RP; Nelson SM; Klicker RE
    Antimicrob Agents Chemother; 1982 May; 21(5):848-51. PubMed ID: 6213200
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280 DL 8280) and nalidixic acid analogues.
    Seibert G; Limbert M; Klesel N
    Eur J Clin Microbiol; 1983 Dec; 2(6):548-53. PubMed ID: 6230226
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tentative interpretive standards for disk diffusion susceptibility testing with norfloxacin (MK-0366, AM-715).
    Shungu DL; Weinberg E; Gadebusch HH
    Antimicrob Agents Chemother; 1983 Feb; 23(2):256-60. PubMed ID: 6220671
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The comparative activity of norfloxacin with other antimicrobial agents against Gram-positive and Gram-negative bacteria.
    Corrado ML; Cherubin CE; Shulman M
    J Antimicrob Chemother; 1983 Apr; 11(4):369-76. PubMed ID: 6222023
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [In vitro and in vivo antibacterial activities of sulopenem, a new penem antibiotic].
    Komoto A; Otsuki M; Nishino T
    Jpn J Antibiot; 1996 Apr; 49(4):352-66. PubMed ID: 8786626
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the antimicrobial removal device when used with the BACTEC blood culture system.
    Strand CL
    Am J Clin Pathol; 1982 Dec; 78(6):853-6. PubMed ID: 6756125
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activity of faropenem and imipenem for ciprofloxacin-resistant bacteria.
    Piddock LJ; Johnson MM; Webber MA
    J Antimicrob Chemother; 2003 Sep; 52(3):500-2. PubMed ID: 12917244
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activity of imipenem against gram-positive anaerobic bacteria.
    Dubreuil L; Devos J; Romond C
    Int J Clin Pharmacol Res; 1987; 7(1):39-43. PubMed ID: 3473047
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Norfloxacin and the antibacterial gamma pyridone beta carboxylic acids.
    Newsom SW; Matthews J; Amphlett M; Warren RE
    J Antimicrob Chemother; 1982 Jul; 10(1):25-30. PubMed ID: 6213593
    [No Abstract]   [Full Text] [Related]  

  • 53. In vitro activity of imipenem and six other beta-lactam antibiotics against aminoglycoside resistant gram-negative bacilli.
    Bujdáková H; Kallová J; Lausová A; Kettner M
    Microbios; 1995; 84(339):87-90. PubMed ID: 8628124
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin.
    Vuye A; Pijck J
    Antimicrob Agents Chemother; 1985 Apr; 27(4):574-7. PubMed ID: 3859244
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Activity of cephems and carbapenems against clinically isolated Mycobacterium abscessus].
    Ito K; Hashimoto K; Ogata H
    Kekkaku; 2003 Sep; 78(9):587-90. PubMed ID: 14577345
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative in vitro studies of nalidixic acid, oxolinic acid, and a new analog with thieno (2,3-b) pyridine structure.
    Gilis PM; Haemers A; Pattyn SR
    Antimicrob Agents Chemother; 1978 Mar; 13(3):533-5. PubMed ID: 263890
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro activity of ceftazidime, cefepime and imipenem on 1,005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams.
    Bonfiglio G; Marchetti F
    Chemotherapy; 2000; 46(4):229-34. PubMed ID: 10859428
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antimicrobial activity of imipenem and SCH34343 against Legionella species.
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1987 Apr; 6(4):307-9. PubMed ID: 3472705
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [In vitro antibacterial action of norfloxacin].
    Fabio U; Provvisionato CA; Tampieri A; Quaglio GP
    G Ital Chemioter; 1983; 30(1):53-9. PubMed ID: 6229443
    [No Abstract]   [Full Text] [Related]  

  • 60. Susceptibility of ceftazidime and other cephalosporins to a range of beta-lactamases and their potential as inducing agents.
    Mouton RP; Bongaerts GP; van Gestel MH
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():147-52. PubMed ID: 19802978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.